Adoptive T cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma: a phase I clinical study

Meidenbauer, Norbert; Vogl, Sandra; Laumer, Monika; Heymann, Jana; Andreesen, Reinhard; Mackensen, Andréas

doi:10.1186/1475-2867-4-s1-s10

Cancer Cell Int

2004

DOI: 10.1186/1475-2867-4-s1-s10

|View full text |Cite

Adoptive T cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma: a phase I clinical study

Norbert Meidenbauer

Sandra Vogl

Monika Laumer

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

Publication Types

Select...

Book1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Immunotherapy of Uveal Melanoma

Bosch

2011

Current Concepts in Uveal Melanoma

View full text Add to dashboard Cite

Uveal melanoma is a malignancy with exceptional features for treatment with immunotherapy. Primary uveal melanoma can be treated with a variety of therapies that may limit the growth of the primary tumor in the eye and partially preserve vision. However, none of these treatment modalities prevents the development of metastases, which predominantly arise in the liver and universally remain fatal. Novel therapies are being explored for their effectiveness against uveal melanoma metastases and immunotherapy may be a potential option as an alternative or adjunctive treatment, even in the prophylactic setting. Uveal melanoma may be particularly responsive to T-cell-based immunotherapy because it originates in the immune-privileged eye. The localization of the primary tumor in the immune-privileged eye excuses the tumor cells from continuous immunological pressure. This may render primary uveal melanoma more immunogenic than tumor cells from non-privileged sites and allow expression of novel tumor antigens to which the patient's endogenous T cell repertoire is not tolerized. The clinical and genetic differences between cutaneous and uveal melanomas underscore the need for immunotherapy specifically designed for uveal melanoma patients. In this review, the current developments in the field of immunotherapy for uveal melanoma are discussed, with a special emphasis on T-cell-based strategies.

show abstract

Immunotherapy of Uveal Melanoma

Bosch

2011

Current Concepts in Uveal Melanoma

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Adoptive T cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma: a phase I clinical study

Cited by 1 publication

References 0 publications

Immunotherapy of Uveal Melanoma

Immunotherapy of Uveal Melanoma

Contact Info

Product

Resources

About